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insufficiency in a tertiary care setting.9 In these situations,
the vascular surgeon must either splice multiple segments
of vein together or elect to use prosthetic conduit for arte-
rial reconstruction.
Spliced vein bypass grafting procedures involve inci-
sions to expose both the inflow and outflow arteries and
incisions to harvest the conduit. This may increase opera-
tive time and the incidence of postoperative complica-
tions. The conduit may be residual greater saphenous vein,
lesser saphenous vein, arm vein (basilic or cephalic), or
some combination of these.10-15 Results for these spliced
vein bypass grafting procedures are variable. Two-year sec-
ondary patency rates have been reported from 23% to as
much as 73%.16-18
The sole use of prosthetic conduit in bypass grafts
extending below the knee for limb-threatening ischemia
has a significantly poorer patency rate as compared with
autologous vein grafting. The primary patency rates for
prosthetic bypass grafts to infrageniculate arteries are 42%
to 58% and 26% to 30% at 1 and 3 years, respectively.1-5
The poor long-term patency rate of prosthetic bypass
grafting has inspired the development of several adjunctive
techniques to improve results, such as the addition of dis-
tal arteriovenous fistulae.19-22 Another technique involves
A single-piece autologous vein, either in situ or
reversed, is currently the best conduit available for arterial
reconstruction extending below the knee for limb-threat-
ening ischemia.1-6 However, because of prior venous
surgery and lower extremity or coronary bypass grafting
procedures, adequate single segments of vein may be
unavailable to the vascular surgeon.7,8 There are a grow-
ing number of patients in whom the choice of conduit
remains problematic because of a lack of a single piece of
usable vein. This group has been estimated to be 40% to
50% or more of patients with limb-threatening arterial
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Objective: Single-piece vein remains the conduit of choice in patients who need bypass grafting for limb salvage. When
this option is not available, two of the remaining options are prosthetic bypass graft or several segments of vein spliced
together. In this study, we compare spliced vein bypass grafting versus polytetrafluoroethylene grafting with a distal
vein cuff in patients with limb-threatening ischemia. 
Methods: Between 1996 and 2000, 39 bypass grafting procedures in 36 patients were performed for limb-threatening
ischemia. These procedures were prospectively randomized to either spliced vein bypass grafting (spliced group, 19
bypass grafts) or polytetrafluoroethylene grafting with a distal vein cuff (cuff group, 20 bypass grafts). All the patients
in the cuff group underwent anticoagulation therapy with warfarin sodium after surgery. The inclusion criteria
included: no single-piece vein option for bypass grafting, adequate vein for splice, no composite sequential option, and
limb-threatening ischemia. The demographics were similar between the two groups.
Results: The primary patency rate at 2 years was 44% and 49% for the spliced and cuff groups, respectively. In the spliced
group, seven of 19 bypass grafts underwent revision in the follow-up period, and two of 20 cuffed bypass grafts were
successfully revised. The secondary patency rate was 87% and 59% (P < .05), with limb salvage rates of 94% and 85%
for spliced and cuff groups, respectively. Four patients in the spliced vein group needed reoperation for wound com-
plications related to vein harvest. One polytetrafluoroethylene graft needed removal for infection. Two early mortali-
ties occurred in the spliced group, one from myocardial infarction and one from stroke. The overall survival rate at 2
years between the two groups was 67% and 100% for the spliced and cuff groups, respectively (P < .05).
Conclusion: Although this is a preliminary report, it appears that both spliced vein bypass grafting and polytetrafluo-
roethylene bypass grafting with a distal vein cuff produce acceptable limb salvage rates. The secondary patency rate for
spliced vein is better, but these bypass grafts more often need revision or reoperation for wound complications. (J Vasc
Surg 2002;35:299-306.)
the interposition of a small cuff of autologous vein at the
distal anastomosis.23-26 These vein cuffs require a 4-cm to
7-cm segment of vein and have recently been reported to
increase the patency rate to 79% at 4 years with a limb sal-
vage rate of 63%.27 This technique not only improves
patency rates to rival the rates of spliced autologous vein
but also requires only the incisions for the inflow and out-
flow vessels and possibly a third small incision to harvest
the vein cuff. Theoretically, these bypass grafting proce-
dures could be performed in less time with lower morbid-
ity rates as compared with the splicing of several segments
of vein together.
We hypothesized that polytetrafluoroethylene bypass
grafting with a distal vein cuff and postoperative warfarin
sodium therapy will function as well as spliced vein in
below-knee and tibial bypass grafting procedures per-
formed for limb salvage. We studied this theory in a ran-
domized prospective fashion with a focus on bypass graft
patency and limb salvage rates, operative time, and peri-
operative morbidity rates.
METHODS AND MATERIALS
The study design was a single-center, prospective ran-
domized trial and was approved by the Committee on
Research Involving Human Subjects at Albany Medical
College, Albany, NY. To qualify for this study, patients
were required to meet several inclusion criteria: 1, pres-
ence of limb-threatening ischemia; 2, no one-piece vein
bypass graft option available either in situ or reversed; 3,
presence of adequate segments of vein available for splice
on the basis of duplex scan venous mapping13 (adequacy
was defined as compliant vein greater than 2 mm in size);
4, no contraindication to anticoagulation therapy; 5, out-
flow to either the below-knee popliteal or tibial artery; 6,
no composite sequential bypass graft option, which we
consider to be an above-knee femoral-popliteal bypass
graft, an intervening healthy segment of artery, then a sin-
gle piece of vein to a distal artery; and 7, ability to give
informed consent.
The patients who met these criteria were random-
ized to either a polytetrafluoroethylene bypass graft with
an interposition vein cuff, as described by Tyrell and
Wolfe,23 or to a spliced vein bypass graft. The Wolfe
boot was selected because, in the authors’ experience, it
maintained a streamlined profile and made wound clo-
sure simpler. In addition, it was the technique with
which the authors had the most experience. Inflow and
outflow arteries were determined with preoperative
angiographic results. In general, at least two surgeons
were present for every surgery. In cases that required
arm vein harvest, occasionally a third member of the
team would prepare vein for harvest. All the procedures
were performed with loupe magnification and headlight
illumination.
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Table I. Patient demographics
Vein cuff Spliced vein P value
Age (years) 68.2 ± 2.7 71.4 ± 2.3 NS
Age range (years) 50 – 87 53 – 91 NS
Male patients 12 (60%) 10 (52.6%) NS
Female patients 8 (40%) 8 (47.4%) NS
Ischemic category* 4.80 ± 0.09 4.84 ± 0.09 NS
Preoperative ABI 0.32 ± 0.07 0.25 ± 0.07 NS
*Data for ischemic category on basis of suggested reporting criteria from Rutherford et al.31
NS, Not significant; ABI, ankle-brachial index.
Fig 1. Cumulative life table primary patency rates for polytetra-
fluoroethylene grafts with distal vein cuff or spliced vein bypass
grafts.
Fig 2. Cumulative life table secondary patency rates for polytet-
rafluoroethylene grafts with distal vein cuff or spliced vein bypass
grafts.
In patients who underwent vein cuff bypass grafting,
the proximal end of a 6-mm polytetrafluoroethylene graft
was sewn to the inflow artery and directly tunneled to the
distal exposure. A vein segment of approximately 4 cm was
harvested for the cuff. The depth of the boot was 3 to 4
mm, and the arteriotomy was made as close to 2 cm in
length as possible. The vein was split longitudinally, and
the short edge was sewn to the toe of the artery with an
8-0 prolene suture. The distal portion of the venous panel
then was sewn around the arteriotomy. The venous panel
then was sutured along the anterior edge of the artery
until it was complete and was tied to the other end of the
suture. Redundant vein was then resected, and the anasto-
mosis was continued to the terminal edge at the apex. The
heel was cut back such that the polytetrafluoroethylene
graft was attached to the cuff at a 30-degree angle with a
7-0 prolene suture.
After the operation, all the patients with vein cuff
reconstructions underwent anticoagulation therapy with
heparin to achieve a partial thromboplastin time of 1.5 to
2 time-control levels. They were subsequently placed on
warfarin sodium therapy to maintain an international nor-
malized ratio of 2.0 to 3.0. 
The spliced vein bypass grafts were created as previ-
ously described.17 The excised veins were harvested and
distended at a controlled pressure of 250 mm Hg with a
mixture of heparin/dextran/papaverine hydrochloride.
The selection of the conduit was made on the basis of the
preoperative duplex scan examination results. In general,
the veins considered to be of the best quality were selected.
Veins without significant taper were reversed, and veins
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with a marked taper were sewn in a nonreversed configu-
ration, and their valves were incised with a modified Mills’
valvulotome (American V Mueller, Chicago, Ill).
Venovenostomy was usually performed in an end-to-
end fashion with an 8-0 polypropylene suture. Conduits
were constructed, with an effort to place the larger conduits
proximally and the smallest distally. Vein wall ischemia was
minimized in all cases with perfusion with arterial blood
after the completion of the proximal anastomosis.28 New
arterial blood was allowed to perfuse the bypass graft at least
every 15 minutes. More distal segments were harvested
only after the proximal segments were perfused. All the
patients underwent patency assessment with Doppler ultra-
sound scanning in the operating room and completion
angiography, unless contraindicated by renal insufficiency
or contrast allergy.
Follow-up examination in both groups involved phys-
ical examination, pulse volume recordings, segmental
pressures, and duplex ultrasound scan imaging. These
examinations were performed within 30 days, then at 3, 6,
9, and 12 months, and then every 6 months thereafter.
Duplex scan imaging of spliced veins included the entire
length of the bypass graft. Vein cuff examinations included
measuring the size of the cuff and recording the distal flow
rate. A stenosis was suggested by a segmental increase in
peak systolic velocity two and a half times that of the prox-
imal bypass graft flow without a change in bypass graft
diameter warranting further evaluation with angiography.
All the data reported were presented and analyzed in
accordance with the Ad Hoc Committee on Reporting
Standards, The Society for Vascular Surgery/North
Fig 3. Cumulative life table limb salvage rates for patients with
distal vein cuff grafts or spliced vein bypass grafts.
Fig 4. Cumulative survival rates for patients with distal vein cuff
grafts or spliced vein bypass grafts.
Table II. Inflow artery
Vein cuff Spliced vein P value
Graft/iliac artery 5 (25%) 2 (10.5%) NS
Common femoral artery 15 (75%) 10 (52.6%) NS
Superficial femoral artery 0 (0%) 4 (21.1%) .037
Profunda femoral artery 0 (0%) 3 (15.8%) NS
NS, Not significant.
American Chapter, International Society for Cardio-
vascular Surgery.29 Patency, survival, and limb salvage
rates were calculated with life table. Comparisons of life
table estimates were performed with the Mantel-Cox log
rank test of significance. Comparison of continuous data
was performed with Student t test. Noncontinuous data
were analyzed with χ2 test for association. Significance was
accepted at a P value of less than .05.
RESULTS
Between 1996 and 2001, 39 patients who were seen at
the Albany Medical Center fulfilled the inclusion criteria
for this trial. Twenty procedures were randomized to poly-
tetrafluoroethylene bypass grafting with a distal vein cuff,
and 19 procedures were spliced vein bypass grafting. The
patient demographics between the two groups are given in
Table I. Randomization between the two groups was
equivalent in terms of sex and age distribution. The groups
were also similar in terms of presenting ankle-brachial
index and ischemic category. Comparison results of vascu-
lar disease risk factors showed the groups were similar in
terms of diabetes, lipids, renal disease, carotid disease, pul-
monary status, hypertension, and tobacco use. The spliced
vein group had a significantly higher cardiac risk status as
compared with the vein cuff group (P < .0001).
Analysis results of why patients did not have a single
piece of saphenous vein for distal bypass grafting revealed
that four of 20 patients (20%) had inadequate segments of
vein, either too small (<2.0 mm), thrombosed, or scle-
rotic. Nine of 20 patients (45%) had undergone a prior
harvest for coronary artery bypass grafting, and 17 of 20
patients (85%) had undergone prior lower extremity
bypass grafting with greater saphenous vein. These num-
bers were similar in the spliced group in which one of 19
patients (5.2%) had inadequate segments, nine of 19
patients (47%) had prior coronary artery bypass grafting,
and 18 of 19 patients (95%) had prior lower extremity
bypass grafting. These represented redo operations in 16
of 19 spliced vein bypass grafting procedures and 15 of 20
vein cuff bypass grafting procedures.
The inflow and outflow vessels are shown in Tables II
and III. Most bypass grafts in the vein cuff group were
derived from the common femoral or external iliac artery,
with none originating from the superficial or deep femoral
artery. On the other hand, seven of 19 spliced vein bypass
grafts originated from the superficial or deep femoral artery
because this decreased the length of vein needed. The
remainder were from the common femoral or aortob-
ifemoral graft limbs. Construction of the spliced veins con-
sisted of four segments in one patient, three segments in
three patients, and two segments in the remaining 15 bypass
grafts. Six bypass grafts had segments of residual greater
saphenous vein, 13 bypass grafts contained lesser saphenous
vein, 14 bypass grafts contained arm vein, and only one
bypass graft was constructed entirely of spliced arm vein.
Outflow arteries were fairly evenly distributed between
the groups, although the vein cuff group had six bypass
grafts terminating on the anterior tibial artery (30%) as
compared with the spliced vein group (5.3%; P < .05). No
vein cuff bypass graft used the dorsalis pedis artery as out-
flow. Run-off scores were not significantly different
between the two groups as per grading calculation.29
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Table III. Outflow artery
Vein cuff Spliced vein P value
Below-knee popliteal artery 4 (20%) 4 (21.0%) NS
Anterior tibial artery 6 (30%) 1 (5.3%) .05
Peroneal artery 6 (30%) 8 (42.1%) NS
Posterior tibial artery 4 (20%) 3 (15.8%) NS
Dorsalis pedis artery 0 (0%) 3 (15.8%) NS
Runoff score* 1 1 NS
*Runoff score on basis of suggested reporting criteria from Rutherford et al.31 Data represented are mode for each group.
Because these bypass grafting procedures were performed to single patent infrageniculate artery, recipient artery receives 3 weighting units. Zero is assigned
to completely patent arch, 1 for patent arch without retrograde flow, 2 for diseased or partially occluded arch, and 3 for no arch visualized.
NS, Not significant.
Table IV. Perioperative mortality and morbidity severity
Vein cuff Spliced vein
Mortality 0 (0%) 2/19 (11%)
Morbidity (severity score*)
Cardiac (average) 2 (1) 7 (1.7)
Stroke (average) 1 (2) 1 (2)
DVT (average) 0 2 (2)
Hemorrhage (average) 1 (1) 4 (3)
Renal insufficiency (average) 1 (3) 1 (2)
Wound complications (average) 2 (1.5) 3 (1)
Graft infection (average) 1 (3) 0
*Severity score on basis of suggested reporting criteria from Rutherford et al.31
DVT, Deep venous thrombosis.
Operative time, blood loss, and hospital length of stay
were all significantly less in the vein cuff group as com-
pared with the spliced vein bypass graft group. Operative
time averaged 177.7 ± 9.2 minutes in the cuff group and
262.6 ± 20.8 minutes in the splice group (P < .05). Blood
loss and hospital length of stay was 236 ± 32.5 mL and
9.20 ± 1.2 days, respectively, for the patients who under-
went vein cuff grafting and 392 ± 54 mL and 12.5 ± 0.8
days, respectively, in the patients who underwent spliced
vein grafting (P < .05). In the cuff group, three patients
underwent amputations after bypass grafting, these
included two transmetatarsal amputations and one digital
amputation. In the spliced group, two digital amputations
and one transmetatarsal amputation were performed at the
initial hospitalization.
The overall perioperative mortality rate was 0% in the
cuff group and 11% in the spliced vein group (P = not sig-
nificant). One patient died from stroke, and one died from
myocardial infarction. Cardiac and bleeding complications
were more frequent and more severe in the spliced vein
group, and renal insufficiency and wound complications
were similar between the two groups. One graft infection
occurred in the cuff group (Table IV).
Primary patency rates for these bypass grafts are shown
in Fig 1 (Appendix A, online only) for the cuff and spliced
vein bypass grafts. The 2-year primary patency rates for cuff
and spliced vein bypass grafts were 50% and 44%, respec-
tively, with these values not being significantly different.
Only one patient in the cuff group was lost to follow-up
examination at 1 month. Two cuff bypass grafts needed
revision. One patient who needed excision of an intimal
hyperplastic lesion at the distal anastomosis and one
stenotic proximal anastomosis underwent revision. In the
spliced vein bypass grafts that needed revision, only one
was the result of intimal hyperplasia at a venovenostomy.
The remaining six bypass graft stenoses were mid-vein
lesions. Five of these were in arm vein segments, and one
was in a segment of lesser saphenous vein. All these lesions
in the spliced vein were identified and revised within the
first year. This resulted in a secondary patency rate at 2
years of 52% and 86%, respectively, (Fig 2; Appendix B,
online only) for the cuff and spliced vein groups (P < .05).
A total of 10 bypass graft failures occurred in the cuff
group. Two of these were revised as described. In four of
these patients, failure of the bypass graft was temporally
related to cessation of warfarin sodium therapy by their pri-
mary physician. Two of these patients underwent unsuc-
cessful lytic treatment and new bypass grafting procedures.
Compliance with anticoagulation therapy was reliable in
the remaining patients. Individual international normalized
ratio values were followed and dosages adjusted by nurses
in our institution. There were no bleeding complications
related to warfarin sodium therapy in this study. In the
group of patients with failed cuff bypass grafts, seven of 10
patients went on to have a splice vein bypass grafting pro-
cedure performed and one patient had another vein cuff
bypass grafting procedure performed. These patients con-
tinued on with limb salvage. 
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Limb salvage was not significantly different at 2 years,
with 85% and 94% rates for the cuff and splice groups,
respectively (Fig 3; Appendix C, online only). Overall sur-
vival rate between the two groups was significantly differ-
ent, with rates of 100% and 67% at 2 years for the cuff and
splice groups, respectively (P < .05; Fig 4; Appendix D,
online only).
DISCUSSION 
Multiple reports have shown the superiority of vein to
prosthetic materials for patients who need distal bypass
grafting for limb-threatening ischemia.1,6,30 In the
absence of an adequate length of single-piece autogenous
vein, other options available for a bypass graft to the infra-
geniculate level include the use of distal graft origins,
spliced vein, composite-sequential grafting, preserved
vein, or prosthetic material. When patients need more dis-
tal bypass graft, the reasonable available options are either
spliced vein or a prosthetic bypass graft with or without an
adjunctive procedure (distal fistula or distal vein cuff).
Prosthetic bypass grafting to distal arteries is preferable to
amputation in patients without adequate vein. However,
prosthetic bypass grafting alone has a relatively dismal fate,
with patency rates of 39% reported at 3 years for polytet-
rafluoroethylene grafts.31 The addition of chronic antico-
agulation therapy has improved this rate to 58% in patients
who underwent adequate anticoagulation therapy.14
Additions of other adjuncts also appear to improve the
patency rate of distal prosthetic bypass grafting. Distal
arteriovenous fistulae constructed at the time of the pros-
thetic bypass grafting have been shown to improve the
patency rate of these grafts. Results with these adjuncts
have shown improvement in patency rate to 48% at 2 years
with distal arteriovenous fistula and to 61% at 3 years for
the common ostium variant of this adjunct, as reported by
Dardik et al.19 Similarly, Ascer et al,20 with a technique
that combined a vein cuff and a fistula, reported a patency
rate of 62% at 3 years, with a limb salvage rate of 77%.
However, from our previous experience, we noted that
creation of the arteriovenous fistula was technically
demanding and time consuming to perform in this diffi-
cult patient population.21,22,32 This observation led us to
begin performing distal vein cuff bypass grafting.
Siegman33 first advocated the use of the venous cuff to
facilitate the performance of anastomoses to calcified
arteries. With this technique, Stonebridge et al34 reported
a patency rate of 59% at 2 years, with a limb salvage rate of
84%. More recently, Neville, Tempesta, and Sidawy27 have
reported superior results of 79% at 4 years with their tech-
nique of a venous patch.
Spliced vein bypass grafting results have also shown
excellent patency and limb salvage rates in this difficult
group of patients. We have reported previous patency rates
of 73% and limb salvage rates of 91% at 2 years.17 More
recently, Chew et al18 reported a patency rate of 70% at 5
years, with a limb salvage rate of 81%. However, in this
study, they noted a bypass graft revision rate of 27% and a
perioperative morbidity rate of 29%, with 11% of this from
early graft failure. They noted a major morbidity rate of
7%. From these data, it is not unreasonable to compare
two procedures in which one may offer lower initial mor-
bidity and mortality rates, even if it may have a slightly
lower long-term patency rate. To date, this report repre-
sents the only prospective trial that compares polytetraflu-
oroethylene graft with an adjunctive vein cuff and
postoperative warfarin sodium therapy with spliced auto-
genous vein bypass graft in patients with limb-threatening
ischemia. We hypothesized that polytetrafluoroethylene
graft with a distal vein cuff would function as well as splice
vein graft in patients with limb-threatening ischemia and
produce reasonable patency and limb salvage rates with
decreased morbidity and mortality rates. For this evalua-
tion, we randomized patients to either spliced vein bypass
grafting or polytetrafluoroethylene bypass grafting with a
distal vein cuff. However, as can be seen, because of the
relatively small numbers of patients in this study, the ran-
domization was not equal. The two groups were equal
regarding all comorbid conditions except for cardiac sta-
tus. This factor may contribute to the higher perioperative
mortality rate and increased number and severity of car-
diac morbidity seen in the spliced vein group. However,
the significantly increased operative time and blood loss in
the spliced vein group may have also contributed to the
higher perioperative mortality and morbidity rates seen in
this group of patients.
The data show that although our patency rates at 2 years
for cuff and spliced veins were 51% and 87%, respectively,
our limb salvage rates were 85% and 94%, respectively. The
crossover between the groups can explain this fact after graft
failure. In fact, seven of 10 patients with a failed cuff bypass
graft went on to successful splice vein bypass grafting and
continued limb salvage. In addition, one of the patients with
failed spliced vein bypass grafting went to undergo cuff
bypass grafting after the bypass graft failed.
The addition of warfarin sodium therapy to the treat-
ment of patients who needed infrapopliteal bypass grafting
with polytetrafluoroethylene is often cited as an important
factor in improving the patency rate of these bypass grafts.
The primary patency rate in the series reported by Flinn et
al14 for infrapopliteal prosthetic bypass grafting was 59% at
2 years in the subgroup of patients who underwent ade-
quate anticoagulation therapy (prothrombin time > 18). If
we performed the same subgroup analysis in our series of
patients, the primary patency rate of patients who under-
went adequate anticoagulation therapy would be 71% at 2
years. This rate rivals that of the recently reported series by
Neville et al27 who reported patency rates of 79% at 4
years. In their discussion, they reinforced the importance
of aggressively maintaining adequate anticoagulation ther-
apy in this group of patients.
Our series shows that polytetrafluoroethylene bypass
grafting with a distal vein cuff can be performed in less
time, with a shorter hospital stay and less blood loss, than
can splice vein bypass grafting and can produce reasonable
patency and limb salvage rates. Also, these prosthetic
bypass grafts may present less risk in terms of perioperative
morbidity and mortality rates. However, in certain situa-
tions, prosthetic material may not be the best option.
Although not discussed, we believe that in patients who
need inframalleolar bypass grafting for limb salvage or who
have invasive foot infections in which the bypass graft
would be in proximity autogenous conduit is preferable
because of the poor performance of prosthetic graft with a
vein cuff at that level.21,35
In conclusion, patients who underwent spliced vein
reconstruction for limb salvage had a trend for superior
patency rates at a cost of increased mortality and morbid-
ity rates. Thus, these results may favor the use of polytet-
rafluoroethylene graft with a vein cuff in patients who
represent higher risk or in whom the quality of remaining
vein segments is questionable. It should be remembered
that these data are preliminary and the numbers small,
thus increasing the chance for a type II statistical error.
The performance of polytetrafluoroethylene bypass graft-
ing with a vein cuff in these situations does not seem to
preclude a subsequent redo procedure with autogenous
conduit, and both types of bypass grafting may achieve
acceptable limb salvage in these patients.
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DISCUSSION
Dr Max P. Levine (Danville, Va). Were all your patients on
preoperative β blockers or ACE inhibitors, and might have you
averted the two mortalities in the spliced vein group?
Dr Paul B. Kreienberg. All the patients have preoperative
assessment by cardiologists. At present, they are more aggressive
with putting patients on β blockers preoperatively and periopera-
tively. Also, for the use of ACE inhibitors, I would have to go
back and look through the data because I do not have those num-
bers for you.
Dr Kevin G. Burnand (London, United Kingdom). Can you
tell me the minimum lowest diameter of your spliced vein? And
did you have any cases of infection in your PTFE graft? And
finally, were your survival data statistically significant?
Dr Kreienberg. Based on the preoperative duplex, we
excluded veins that were less than 2 mm in size. There were some
veins that were still used, if they distended, greater than the size
of an 8-F suction catheter. There was one infection in one of the
Gore-Tex grafts that required graft removal. It was associated
with a proximal anastomosis to an aortobifemoral limb. The
patient required removal of the aortobifemoral limb and sec-
ondary reconstruction.
Dr Burnand. Did that patient lose his leg?
Dr Kreienberg. No. Actually, he had another inflow procedure
performed and a spliced vein bypass performed. So, it was not
immediate limb loss but delayed.
The survival was statistically different, and I think part of this
is a product of the randomization. The trial is so small, and there
was a higher cardiac risk profile in the patients that underwent
spliced vein bypass. So, in terms of survival, we may just be look-
ing at a result of the randomization.
Dr Mounir K. Mabrouk (Alexandria, Egypt). There was a
paper about 10 years ago by Shulman and Schanzer from New
York. It was about the use of deep leg veins, femoral vein use, as
a substitute for veins whenever there was not adequate saphenous
vein, whether shorter arm or whatever. I think there has always
been a taboo about the use of these femoral veins for fear of the
consequences of chronic deep vein insufficiency. But actually,
when performing this, the results were good in regards to the use
of these deep leg veins. My point is, would that be given a con-
sideration with the spliced vein?
Dr Kreienberg. There were no patients in this study where we
used deep leg vein. In the last 2 years, we used deep leg vein twice
and that was when we just needed an additional short segment of
vein to complete a spliced vein. Those were patients that were not
in this study.
We do recognize that it is a potential vein that can be used
for arterial reconstruction, but our experience is limited with it.
So, at least on the initial evaluations, what we included were
branches of the greater, residual greater, and lesser saphenous,
and then arm vein, basilic, and cephalic.
Dr Bauer E. Sumpio (New Haven, Conn). The mechanism of
the beneficial effects of a vein cuff in terms of long-term patency
rate and intimal hyperplasia is not well-established. The prevailing
theory has to do with alterations in hemodynamics and creation
of a stable vortex. Data indicate that you need a certain geometry
in order to get this beneficial vortex. The aspect ratio, the length
versus height, in the construction of your vein cuffs may be
important.
Do you feel that the aspect ratio of vein cuffs is important?
Did you do anything in your study to standardize the manner in
which the vein cuffs are made? It is quite easy to take a piece of
vein and make a little chimney out of it and put the PTFE on it,
but was there consideration in trying to maintain a standard
length versus height of the vein chimney versus the recipient
artery diameter?
Dr Kreienberg. For the distal anastomoses, I used basically just
the back of a scalpel handle, measured 2 cm. So, we all standard-
ized the length of the arteriotomy.
The height of the cuff is varied with the surgeon. But I agree,
because some of the cuffs were created with arm veins, when you
panel those veins, they get to be pretty tall. So, all those get
trimmed down. We did not really standardize the height of the
cuffs, but you are right, that may be important.
The duplex data we have looked at were flow rates. Also, all
the cuffs tend to enlarge over time, which is one of the other
things that we did measure. Later in the series, we did actually
keep the height of the cuff a little bit lower and made the heel the
lowest part to streamline the anastomosis.
Dr Robert McLafferty (Springfield, Ill). I was wondering why
you used a 6-mm PTFE instead of an 8-mm? There is some clin-
ical data showing that the larger the conduit the better the
patency. Smaller diameter conduits have a smaller blood vol-
ume/surface area ratio, possibly making them more susceptible to
thrombosis. Please comment.
Dr Kreienberg. What is going to determine the flow rates for
these grafts is the distal artery that it is going through. The paten-
cies you quote for 8-mm and 6-mm grafts were above-knee
popliteal bypasses and not for tibial level.
We selected the 6-mm graft mainly for technical reasons. The
space you have to close over these grafts is fairly limited. And so,
if you can keep that graft smaller, you can get better soft tissue
coverage over the graft, especially when you are working down
toward the malleolus.
Dr McLafferty. The other follow-up question I have is your
opinion on the multi-team approach. Some centers use a multi-
team approach with spliced vein, and that obviously decreases
operative time. What is your feeling on that in regards to the
complication rates with your spliced vein group?
Dr Kreienberg. All the cases had at least two surgeons present.
In some of the spliced vein cases, if we did have a third person,
they would do the arm vein harvest. One half of the bypasses in
the spliced vein group contained segments of arm vein, but we
did not consistently have three surgeons at those surgeries.
Dr Mark E. Kahn (Englewood, NJ). I have the unique advan-
tage of having been at Albany and at Englewood where the in situ
and the Biograft have been used. The approach in Englewood is
to use a Biograft to the tibial vessels and to do AV fistulas distally,
particularly when the vessels are bad.
When we do this, we are really applying half a vein cuff to
that anastomosis, not a circular one. I wonder if perhaps it is the
effect of the half cuff rather than the fistula and the flow.
Additionally, a Biograft has better compliance than PTFE; I am
not sure which of these factors has the most effect.
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